Form 4: Avidity Biosciences CSO Acquires Shares via PSU Vesting

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, acquired 27,500 shares of common stock through PSU vesting, while 13,695 shares were withheld for tax purposes.

Summary

• W. Michael Flanagan, Chief Scientific Officer of Avidity Biosciences, Inc. (RNA), reported changes in beneficial ownership.
• Acquired 27,500 shares of common stock on December 17, 2025, through the vesting of performance-based restricted stock units (PSUs).
• The PSUs were originally granted on October 30, 2024, and settled on December 17, 2025, for tax planning purposes.
• Disposed of 13,695 shares of common stock on December 17, 2025, at a price of $71.87 per share, to cover tax withholding obligations.
• Following these transactions, beneficial ownership stands at 94,000 shares of common stock.
• The acquired shares remain subject to recoupment by the Issuer if employment is terminated by the Issuer for cause or by the Reporting Person without good reason.

Sentiment

Score: 7

Explanation: The vesting of performance-based restricted stock units for a key executive is a positive indicator of past performance achievement and executive alignment, despite the routine tax withholding.

Positives

• The vesting of 27,500 performance-based restricted stock units indicates the achievement of performance targets by the Chief Scientific Officer.
• The transaction aligns the Chief Scientific Officer's interests with those of shareholders through increased direct ownership.

Negatives

• 13,695 shares were withheld by the Issuer to cover tax withholding, reducing the net shares received by the executive.
• The acquired shares are subject to a recoupment clause under specific termination conditions, adding a potential future contingency.

Risks

• The shares acquired upon PSU vesting are subject to recoupment by Avidity Biosciences if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The vesting and issuance of shares from PSUs represent a minor, expected increase in outstanding shares as part of executive compensation, aligning management incentives with shareholder value.
• Employees: This transaction reflects standard executive compensation practices, which can serve as a benchmark or expectation for other high-level employees.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of performance-based restricted stock units and subsequent tax withholding for the Chief Scientific Officer. Such transactions are common for executive compensation and do not typically signal a fundamental change in the company's prospects or warrant a change in investment recommendation. The vesting indicates past performance achievement, which is a neutral to slightly positive signal, but the overall impact on the stock's valuation or future performance is minimal.

Keywords

Avidity Biosciences, RNA, W. Michael Flanagan, Form 4, insider transaction, PSU vesting, restricted stock units, Chief Scientific Officer, stock acquisition, tax withholding